The KEAP1 (Kelch-like ECH-associated protein 1)/NRF2 (Nuclear factor (erythroid-derived 2)-like 2) is a master pathway regulator of antioxidants and cellular stress responses and is clearly implicated in neoplastic progression and resistance of tumor cells against chemo- and radio-treatments [1], so the consequent enhancement of NRF2 expression is becoming a new potential target of anticancer therapeutic approaches [2]. Here, KEAP1 is linked to neoplasm.